1. Merck Signs a Clinical Trial Collaboration with FLX Bio, for a Combination Therapy

Published: 5 Nov, 2018 |Tags: Merck, Signs, Clinical Trial, Collaboration, FLX Bio, Combination Therapy, Keytruda

2. Amgen to Present Long-Term Safety-Efficacy Data of Repatha (evolocumab) in Multiple studies, at AHA 2018

Published: 5 Nov, 2018 |Tags: Amgen, Present, Long-Term, Safety-Efficacy Data, Repatha (evolocumab), Multiple studies, AHA 2018

3. Eli Lilly and NextCure Signs a Multi-Year Collaboration to Develop Novel Immune-Oncology Therapies

Published: 5 Nov, 2018 |Tags: Eli Lilly, NextCure, Signs, Multi-Year, Collaboration, Develop, Novel, Immuno-Oncology Therapies

4. Abeona Signs Exclusive License Agreement with Regenxbio to Develop and Commercialize NAV AAV9 Vector

Published: 5 Nov, 2018|Tags: Abeona, Signs, Exclusive, License, Agreement, Regenxbio, Develop, Commercialize, NAV AAV9 vector

5. Boehringer Ingelheim (BI) & Eli Lilly Reports RWE Results of Jardiance (empagliflozin) in EMPRISE study, Presented at AHA 2018

Published: 5 Nov, 2018 |Tags: Boehringer Ingelheim (BI), Eli Lilly, Reports, RWE, Results, Jardiance, (empagliflozin), EMPRISE study, Presented, AHA 2018

6. Sage Reports Voting Results from FDA Advisory Committees for Zulresso (brexanolone) to Treat Postpartum Depression (PPD)

Published: 2 Nov, 2018 |Tags: Sage, Reports, Voting, Results, FDA Advisory Committees, Zulresso (brexanolone), Treat, Postpartum Depression (PPD)

7. Coherus’ Udenyca (pegfilgrastim-cbqv) Receives the US FDA Approval for Patients Receiving Myelosuppressive Chemotherapy

Published: 2 Nov, 2018 |Tags: Coherus’, Udenyca, (pegfilgrastim-cbqv), Receives, the US FDA, Approval for Patients Receiving Myelosuppressive Chemotherapy

8. Lupin Recalls its 6,752 Testosterone Bottles from the US market

Published: 2 Nov, 2018|Tags: Lupin, Recalls, 6,752, Testosterone Bottles, the US market, class III recall